Lung cancer immunotherapy: progress, pitfalls, and promises
A Lahiri, A Maji, PD Potdar, N Singh, P Parikh, B Bisht… - Molecular cancer, 2023 - Springer
Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Therapeutic options for lung cancer treatment include surgery, radiation therapy …
Exploring treatment options in cancer: tumor treatment strategies
Traditional therapeutic approaches such as chemotherapy and radiation therapy have
burdened cancer patients with onerous physical and psychological challenges …
burdened cancer patients with onerous physical and psychological challenges …
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
AJ de Langen, ML Johnson, J Mazieres… - The Lancet, 2023 - thelancet.com
Background Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS G12C.
We compared the efficacy and safety of sotorasib with a standard-of-care treatment in …
We compared the efficacy and safety of sotorasib with a standard-of-care treatment in …
Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation
Abstract Background Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds
KRASG12C, locking it in its inactive state. Adagrasib showed clinical activity and had an …
KRASG12C, locking it in its inactive state. Adagrasib showed clinical activity and had an …
Targeting angiogenesis in oncology, ophthalmology and beyond
Angiogenesis is an essential process in normal development and in adult physiology, but
can be disrupted in numerous diseases. The concept of targeting angiogenesis for treating …
can be disrupted in numerous diseases. The concept of targeting angiogenesis for treating …
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
LE Hendriks, KM Kerr, J Menis, TS Mok… - Annals of …, 2023 - annalsofoncology.org
Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …
Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I …
K Park, EB Haura, NB Leighl, P Mitchell… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor
(EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …
(EGFR) exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Background Oncogenic alterations in RET have been identified in multiple tumour types,
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety …
FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC
EC Nakajima, N Drezner, X Li, PS Mishra-Kalyani… - Clinical Cancer …, 2022 - AACR
Abstract On May 28, 2021, the FDA granted accelerated approval to sotorasib (Lumakras,
Amgen) for the treatment of adults with advanced non–small cell lung cancer (NSCLC) with …
Amgen) for the treatment of adults with advanced non–small cell lung cancer (NSCLC) with …